{"id":"W4387810225","doi":"10.1016/j.annonc.2023.09.2760","title":"1812P Exploration of germline (g) vs somatic (s) origin of homologous recombination repair (HRR) gene alterations and potential associations with antitumor activity in the HRR-deficient population from TALAPRO-2","year":2023,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"ca_institutions":"","funders":"Chugai Pharmaceutical; Australian and New Zealand Urogenital and Prostate Cancer Trials Group; PharmaMar; Novartis Farmacéutica; Cilag; Astellas Pharma; Eisai; Ipsen; Clovis Oncology; Astellas Pharma Canada; Daiichi Sankyo Europe; Sanofi; Exelixis; F. Hoffmann-La Roche; Gilead Sciences; MacroGenics; Astellas Foundation for Research on Metabolic Disorders; Amgen; Pfizer; AstraZeneca; Eli Lilly and Company","keywords":"Medicine; CHEK2; Prostate cancer; Population; Internal medicine; Oncology; Enzalutamide; Cancer; Cancer research; Androgen receptor; Germline mutation; Genetics; Biology; Mutation; Gene","routes":{"ca_aff":false,"ca_fund":true,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":true},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0001205013,0.0002833061,0.0002016792,0.001006883,0.0003324673,0.0002937456,0.0003438193,0.0003706178,0.007387473],"category_scores_gemma":[0.0002430993,0.0001091289,0.0002967881,0.0004516364,0.0002371441,0.0001154101,0.0002601254,0.0004894205,0.0006709881],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0001124324,"about_ca_system_score_gemma":0.00008426986,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001005935,"about_ca_topic_score_gemma":0.0006161571,"domain_scores_codex":[0.9998783,0.00001248197,0.00001108475,0.00004301062,0.00002814681,0.00002703895],"domain_scores_gemma":[0.9998627,0.00003584573,0.00003460349,0.00001056536,0.00001809532,0.00003825694],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","study_design_scores_codex":[0.002385543,0.0003610019,0.06906729,0.00004352587,0.0001187925,0.007236965,0.0003580853,0.0002504436,0.9075484,0.0004990654,0.0003258329,0.01180498],"study_design_scores_gemma":[0.0002472087,0.003462603,0.7803541,0.00002893752,0.0002920861,0.03747703,0.001165992,0.002478592,0.1622366,0.0008702792,0.011339,0.00004771373],"study_design_candidate":"observational","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9970832,0.00007089586,0.0006060634,0.0000642894,0.000007772488,0.00001996284,0.0008807505,0.0000178209,0.00124921],"genre_scores_gemma":[0.9970987,0.00006779134,0.00028559,0.00005965388,0.000009211471,0.00001632382,0.0008474105,0.00001917277,0.001596238],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.007387473,"threshold_uncertainty_score":0.02471352,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.1135546997369735,"score_gpt":0.399816975170919,"score_spread":0.2862622754339454,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}